BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 25770211)

  • 1. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.
    Kamal M; Gbahou F; Guillaume JL; Daulat AM; Benleulmi-Chaachoua A; Luka M; Chen P; Kalbasi Anaraki D; Baroncini M; Mannoury la Cour C; Millan MJ; Prevot V; Delagrange P; Jockers R
    J Biol Chem; 2015 May; 290(18):11537-46. PubMed ID: 25770211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evidence for transactivation within melatonin MT
    Gerbier R; Ndiaye-Lobry D; Martinez de Morentin PB; Cecon E; Heisler LK; Delagrange P; Gbahou F; Jockers R
    FASEB J; 2021 Jan; 35(1):e21161. PubMed ID: 33156577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II).
    Ettaoussi M; Pérès B; Errazani A; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
    Eur J Med Chem; 2015 Jan; 90():822-33. PubMed ID: 25528336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
    Millan MJ; Marin P; Kamal M; Jockers R; Chanrion B; Labasque M; Bockaert J; Mannoury la Cour C
    Int J Neuropsychopharmacol; 2011 Jul; 14(6):768-83. PubMed ID: 20946699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function.
    Baba K; Benleulmi-Chaachoua A; Journé AS; Kamal M; Guillaume JL; Dussaud S; Gbahou F; Yettou K; Liu C; Contreras-Alcantara S; Jockers R; Tosini G
    Sci Signal; 2013 Oct; 6(296):ra89. PubMed ID: 24106342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin Receptor Signaling: Impact of Receptor Oligomerization on Receptor Function.
    Oishi A; Cecon E; Jockers R
    Int Rev Cell Mol Biol; 2018; 338():59-77. PubMed ID: 29699692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
    De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
    Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.
    Ettaoussi M; Sabaouni A; Pérès B; Landagaray E; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    ChemMedChem; 2013 Nov; 8(11):1830-45. PubMed ID: 24031039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
    Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
    Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
    Millan MJ; Brocco M; Gobert A; Dekeyne A
    Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
    Fuchs E; Simon M; Schmelting B
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S17-20. PubMed ID: 16436935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
    Pringle A; Bogdanovskaya M; Waskett P; Zacharia S; Cowen PJ; Harmer CJ
    J Psychopharmacol; 2015 Oct; 29(10):1129-32. PubMed ID: 26174133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of ligand recognition at the human MT
    Stauch B; Johansson LC; McCorvy JD; Patel N; Han GW; Huang XP; Gati C; Batyuk A; Slocum ST; Ishchenko A; Brehm W; White TA; Michaelian N; Madsen C; Zhu L; Grant TD; Grandner JM; Shiriaeva A; Olsen RHJ; Tribo AR; Yous S; Stevens RC; Weierstall U; Katritch V; Roth BL; Liu W; Cherezov V
    Nature; 2019 May; 569(7755):284-288. PubMed ID: 31019306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).
    Ettaoussi M; Sabaouni A; Rami M; Boutin JA; Delagrange P; Renard P; Spedding M; Caignard DH; Berthelot P; Yous S
    Eur J Med Chem; 2012 Mar; 49():310-23. PubMed ID: 22301214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin MT
    Chen M; Cecon E; Karamitri A; Gao W; Gerbier R; Ahmad R; Jockers R
    J Pineal Res; 2020 May; 68(4):e12641. PubMed ID: 32080899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-linked melatonin dimers as bivalent ligands targeting dimeric melatonin receptors.
    Karamitri A; Sadek MS; Journé AS; Gbahou F; Gerbier R; Osman MB; Habib SAM; Jockers R; Zlotos DP
    Bioorg Chem; 2019 Apr; 85():349-356. PubMed ID: 30658234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.
    Pardini M; Cordano C; Benassi F; Mattei C; Sassos D; Guida S; Serrati C; Primavera A; Amore M; Cocito L; Emberti Gialloreti L
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):939-44. PubMed ID: 24636462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT
    Duroux R; Rami M; Landagaray E; Ettaoussi M; Caignard DH; Delagrange P; Melnyk P; Yous S
    Eur J Med Chem; 2017 Dec; 141():552-566. PubMed ID: 29102176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway.
    Sharan K; Lewis K; Furukawa T; Yadav VK
    J Pineal Res; 2017 Sep; 63(2):. PubMed ID: 28512916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.